Monday, September 27, 2021
2:30 - 3:30 PM Eastern Time
Chimeric antigen receptor-T cell therapy targeting the surface receptor CD19 (CAR19) is a potent treatment option for patients with relapsed or chemotherapy-refractory B cell malignancies. Unfortunately, cancer continues to progress in a large subset of these patients due to changes in CD19-presentation on the cancer cells. To eliminate malignant B cells with low CD19 levels, researchers have developed CAR therapies that target the B cell-specific cell surface molecule CD22. While sequential CAR therapy has shown limited success, scientists have now developed a bispecific CAR-T cell that simultaneously targets CD19 and CD22. In this webinar brought to you by IsoPlexis, David Miklos will discuss recent advances in bispecific CAR-T therapy development and critical functional biomarkers for characterizing CAR-T cell product quality.
Meet the Speaker:
David Miklos, MD, PhD
Chief, Blood and Marrow Transplantation and Cellular Therapy
Clinical Director, Cancer Cell Therapy